B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
Read original at benzingaStocks · News reference
Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 8:24 PM
- Checked
- Aug 13, 2026, 8:24 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Caribou Biosciences, Inc. (CRBU)
Filed: 2026-08-13 AccNo: 0001619856-26-000053 Size: 315 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Caribou Biosciences announced positive clinical data for its CRISPR-based CAR-T cell therapies. Vispa-cel demonstrated an 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients with a 17.1-month median progression-free survival. CB-011 showed an 83% complete response rate and 91% MRD negativity in heavily pretreated multiple myeloma patients, with 50% maintaining complete response at 15 months.
Read original at globenewswire-inc